Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

Anti-Cancer Drugs

Volumn 19, Issue 2, 2008, Pages 209-216

  Ling, Jie ^a   Fettner, Scott ^b   Lum, Bert L ^a   Riek, Myriam ^c   Rakhit, Ashok ^b,d  

^a GENENTECH INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MEDICINES COMPANY   (United States)

Author keywords

Erlotinib; Food effect; Pharmacokinetics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LOPERAMIDE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DYSPNEA; FEEDING; FLATULENCE; FOOD DRUG INTERACTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOSSITIS; HEADACHE; HEMATURIA; HUMAN; LOOSE FECES; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; CREATINE KINASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FASTING; FOOD-DRUG INTERACTIONS; GAMMA-GLUTAMYLTRANSFERASE; GLOSSITIS; HEMATURIA; HUMANS; LIVER; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; PATIENT DROPOUTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 37849012740     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f2d8e4     Document Type: Article

References (21)

1. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358744: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291:739-748.
2. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004; 15:503-512.
3. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002; 1:777-783.
4. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-3247.
5. Soulières D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
6. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-2555.
7. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Proc ASCO Gastrointest Cancers Symp 2005; 121:abstract 77.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
9. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al., TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
10. Prescribing Information. Available from www.Tarceva.com.
11. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006; 34:420-426.
12. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 2006; 46:282-290.
13. Lu J, Eppler S, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum B. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80:136-145.
14. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999; 36:233-254.
15. Welling PG. Effects of food on drug absorption. Annu Rev Nutr 1996; 16:383-415.
16. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents. Clin Pharmacokinet 2004; 43:1127-1156.
17. Jones B, Kenward MG. Design and analysis of cross-over trials. New York: Chapman & Hall/CRC; 2003.
18. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Markel Dekker; 2000.
19. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
20. Choi RL, Sun JX, Kochak GM. The effect of food on the relative bioavailability of fadrozole hydrochloride. Biopharm Drug Dispos 1993; 14:779-784.
21. Sioufi A, Sandrenan N, Godbillon J, Trunet P, Czendlik C, Howald H, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5mg single oral administration. Biopharm Drug Dispos 1997; 18:489-497.